• Pharvaris reported publication of qualitative study results in Frontiers in Immunology on disease burden in acquired angioedema due to C1 inhibitor deficiency.
• Findings highlighted frequent misdiagnosis, emergency care, painful attacks, major disruption to daily functioning, with patients relying on off-label treatments.
• The work supported use of established patient-reported outcomes as meaningful trial endpoints, helping define what patients consider improvement.
• Results have already been presented via publication, shaping the design and endpoint selection for the ongoing Phase 3 CREAATE trial of deucrictibant.
• Pharvaris positioned the study as a step toward patient-centered evidence in a condition with no approved preventive or on-demand therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.